By Kelly Knaub ( May 23, 2016, 4:06 PM EDT) -- The Patent Trial and Appeal Board on Friday granted hedge fund manager Kyle Bass and self-described "patent troll" Erich Spangenberg's request to review claims in Citius Pharmaceuticals Inc.'s obesity drug Suprenza, saying they are likely to prevail on their argument that some of the claims are obvious....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.